Table 1.
Driver genes identified from cancer sequencing studies have led directly to drug targets and subsequent therapeutics that have shown significant promise in clinical trials.
| Genotype | Drug | Reference |
|---|---|---|
| PML-RARα translocation | ATRA | Dermime et al. (1993) |
| HER2 amplification | Trastuzumab | Cobleigh et al. (1999) |
| KIT mutation | Imatinib | Demetri et al. (2002) |
| EGFRL858R | Gefitinib, erlotinib | Paez et al. (2004) |
| BRAFV600E | Vemurafenib | Joseph et al. (2010) |
| EML4-ALK | Crizotinib | McDermott et al. (2008) |
| RET | Vandetanib | Wells et al. (2010) |
| BCR-ABL | Imatinib | Druker (2008) |
| ROS | Foretinib | Davare et al. (2013) |